Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M

Nautilus Biotechnology, Inc.

2021-FY EPS reported -$0.60

FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.
Cash, equivalents, investments $362.1M as of Dec 31, 2021; raised ~$345.5M via SPAC merger in June 2021.
Research collaborations with Amgen and MD Anderson; strategic partnership with Abcam for reagents.
Platform commercialization targeted by end of 2023; published PrISM proteomics approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.